- Home
- SNDL vs YMAB Comparison
SNDL vs YMAB Comparison
Compare SNDL & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDL
- YMAB
- Stock Information
- Founded
- SNDL 2006
- YMAB 2015
- Country
- SNDL Canada
- YMAB United States
- Employees
- SNDL N/A
- YMAB N/A
- Industry
- SNDL Pharmaceuticals and Biotechnology
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SNDL Health Care
- YMAB Health Care
- Exchange
- SNDL Nasdaq
- YMAB Nasdaq
- Market Cap
- SNDL 357.7M
- YMAB 386.7M
- IPO Year
- SNDL 2019
- YMAB 2018
- Fundamental
- Price
- SNDL $2.02
- YMAB $8.51
- Analyst Decision
- SNDL
- YMAB Buy
- Analyst Count
- SNDL 0
- YMAB 11
- Target Price
- SNDL N/A
- YMAB $15.02
- AVG Volume (30 Days)
- SNDL 3.7M
- YMAB 1.6M
- Earning Date
- SNDL 07-31-2025
- YMAB 08-08-2025
- Dividend Yield
- SNDL N/A
- YMAB N/A
- EPS Growth
- SNDL N/A
- YMAB N/A
- EPS
- SNDL N/A
- YMAB N/A
- Revenue
- SNDL $692,339,389.00
- YMAB $85,385,000.00
- Revenue This Year
- SNDL $4.13
- YMAB N/A
- Revenue Next Year
- SNDL $4.44
- YMAB $15.23
- P/E Ratio
- SNDL N/A
- YMAB N/A
- Revenue Growth
- SNDL 3.54
- YMAB N/A
- 52 Week Low
- SNDL $1.15
- YMAB $3.55
- 52 Week High
- SNDL $2.40
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- SNDL 76.22
- YMAB 81.50
- Support Level
- SNDL $1.64
- YMAB $8.50
- Resistance Level
- SNDL $1.84
- YMAB $8.54
- Average True Range (ATR)
- SNDL 0.10
- YMAB 0.20
- MACD
- SNDL 0.04
- YMAB 0.42
- Stochastic Oscillator
- SNDL 83.10
- YMAB 99.32
About SNDL SNDL Inc.
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.